3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, 23-26 October 2001
9 December 2001. Related: Conference reports.
2001
Insulin resistance
9 December 2001. Related: Conference reports.
Thyroid function abnormalities
9 December 2001. Related: Conference reports.
Lipodystrophy and metabolic changes in children
9 December 2001. Related: Conference reports, Paediatric care.
Bone studies at lipodystrophy workshop
9 December 2001. Related: Conference reports.
Survey reveals pregnant Zambians support universal nevirapine treatment
9 December 2001. Related: Treatment access.
Delaying antiretroviral therapy may be considered for many patients
9 December 2001. Related: Antiretrovirals.
Correlation between reduction in plasma HIV1 RNA concentration 1 week after start of antiretroviral treatment and longerterm efficacy
9 December 2001. Related: Antiretrovirals.
One week on, one week off experimental regimen might reduce the cost and toxicities of HIV therapy
9 December 2001. Related: Antiretrovirals.
Enteric coated didanosine significantly reduces nausea, bloating, GI upset
9 December 2001. Related: Antiretrovirals, Side effects.
Secondary mutations in HIV-1 protease predict treatment failure in naive patients
9 December 2001. Related: Antiretrovirals, Drug resistance.
Antiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the HERS study
9 December 2001. Related: Antiretrovirals.
Study indicates NNRTI mutations have little effect upon HIV-1 replicative capacity
9 December 2001. Related: Antiretrovirals.
Garlic can impede HIV medication
9 December 2001. Related: PK and drug interactions.
Caution needed with nelfinavir and some lipid-lowering drugs
9 December 2001. Related: PK and drug interactions.
Syncytium inducing viral phenotype halves thymic T cell production in children
9 December 2001. Related: Paediatric care.
Children with advanced disease who take HAART experience immune reconstitution
9 December 2001. Related: Paediatric care.
New US guidelines for the prevention of opportunistic infections in people infected with HIV
9 December 2001. Related: Guidelines.
Incidence and prognosis of AIDS-related lymphoma have improved since the advent of HAART
9 December 2001. Related: Coinfections and complications.
Coinfection does not appear to augment TB infectivity
9 December 2001. Related: TB coinfection.
Detailed picture emerges of how HIV travels into and out of cells
9 December 2001. Related: Basic science and immunology.
High levels of HIV replication shut down anti-HIV immune responses
9 December 2001. Related: Basic science and immunology.
Natural killer cell activity varies with viral burden in HIV-1 infection
9 December 2001. Related: Basic science and immunology.
MDMA: acute effects of ecstasy on T-cell numbers and function
9 December 2001. Related: Other news.
Elevated blood pressure in subjects with lipodystrophy
9 December 2001. Related: Side effects.
Fat distribution is strongly tied to metabolic disturbances in HIV lipodystrophy
9 December 2001. Related: Side effects, Lipodystrophy and metabolic complications.
Eating more often can reduce cholesterol levels
9 December 2001. Related: Side effects, Lipodystrophy and metabolic complications.
TRAIL ligand induces apoptosis of cells infected with HIV in-vitro
9 December 2001. Related: Other news.
DHEA replacement therapy improves quality of life
9 December 2001. Related: Other news.
Medicinal plant ‘fights’ AIDS
9 December 2001. Related: Other news.
Review: treatment of chronic hepatitis
9 December 2001. Related: On the web.
Volume 2 Number 10 December 2001 PDF
1 December 2001. Related: PDFs.
8th European Conference on Clinical Aspects and Treatment of HIV-infection, Athens, 28-31 October 2001
2 November 2001. Related: Conference reports.
HIV drug resistance can develop under HAART at low levels of viraemia
2 November 2001. Related: Conference reports, Drug resistance.
Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients
2 November 2001. Related: Conference reports, PK and drug interactions.
Further reports of benefits of polylactic acid for facial lipoatrophy
2 November 2001. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients
2 November 2001. Related: Conference reports, Drug resistance.
Tenofovir DF 907 study
2 November 2001. Related: Conference reports, Antiretrovirals.
The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir
2 November 2001. Related: Conference reports, Antiretrovirals.
No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz
2 November 2001. Related: Conference reports, PK and drug interactions.
Ritonavir corrects drug interaction between efavirenz and saquinavir
2 November 2001. Related: Conference reports, PK and drug interactions.
Lopinavir/r effective in naive patients after three years of treatment
2 November 2001. Related: Conference reports.
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study
2 November 2001. Related: Antiretrovirals, Side effects.
European CPMP gives positive opinion for European licensing of tenofovir DF
2 November 2001. Related: Antiretrovirals.
EC approves abacavir for use by HIV-infected children
2 November 2001. Related: Antiretrovirals, Paediatric care.
Preventable factors linked to indinavir-associated renal complications
2 November 2001. Related: Side effects.
Patients refractory to HIV treatment require close monitoring
2 November 2001. Related: Drug resistance.
Report on salvage therapy from the 39th annual meeting of the IDSA
2 November 2001. Related: Antiretrovirals, Drug resistance.
HIV infects naive T cells leading to depletion
2 November 2001. Related: Basic science and immunology.
Rapidly progressive HIV case highlights importance of specific immune response
2 November 2001. Related: Basic science and immunology.
CCR5 density on T cells directly correlates with HIV disease progression
2 November 2001. Related: Basic science and immunology.
Human herpes virus 6 prevents CCR5 tropic HIV from spreading in human tissue cultures
2 November 2001. Related: Basic science and immunology.
HIV infection may trigger neurologic disorder
2 November 2001. Related: Coinfections and complications.
Nerve growth factor improves HIV-associated sensory neuropathy
2 November 2001. Related: Side effects, Coinfections and complications.
Daily injection more effective than thrice-weekly interferon alpha-2b for HCV/HIV
2 November 2001. Related: Hepatitis coinfection.
Lipodystrophy in HAART-treated patients may have multifactorial aetiology
2 November 2001. Related: Side effects, Lipodystrophy and metabolic complications.
South Africa hits out at pharmaceutical companies on AIDS drugs
2 November 2001. Related: Other news.
The drug development pipeline
2 November 2001. Related: On the web.
When to start treatment tecommendations
2 November 2001. Related: On the web.
Volume 2 Number 9 November 2001 PDF
1 November 2001. Related: PDFs.
Rapidly ascending neuromuscular weakness associated with nucleoside analogues
2 October 2001. Related: Treatment alerts, Side effects.
Tenofovir DF: results from phase III study released
1 October 2001. Related: Antiretrovirals.
US FDA committee recommends approval for tenofovir
1 October 2001. Related: Antiretrovirals.
HIV suppression in lymphoid tissue varies with antiretroviral regimen
1 October 2001. Related: Antiretrovirals.
Adherence rates lower than 95% are associated with virologic failure
1 October 2001. Related: Antiretrovirals.